Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 14/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906668 | 0.85 | GRM5 (0.46) | GRM5GRM1HTR2B | |
| SCHEMBL4132863 | 0.83 | PIK3CD (0.36) | GRM5GRM1 | |
| SCHEMBL1637883 | 0.78 | GRM5 (0.57) | GRM5GRM1HTR2B | |
| SCHEMBL2483346 | 0.68 | GRM5 (0.67) | GRM5GRM1HTR2B | |
| SCHEMBL11005034 | 0.68 | KDR (0.35) | GRM5GRM1KDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4117859 | 0.68 | GRM5 (0.68) | GRM5GRM1HTR2B | |
| SCHEMBL906671 | 0.67 | GRM5 (0.41) | GRM5GRM1KDM4EALDH1A1HTR2B | |
| SCHEMBL1637329 | 0.67 | HDAC8 (0.39) | KDM4ENPC1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL4110907 | 0.66 | GRM5 (0.66) | GRM5GRM1HTR2B | |
| SCHEMBL3438307 | 0.65 | RAB9A (0.50) | KDM4ENPC1ALDH1A1IRAK4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | GRM5 2795/4885GRM1 4321/4885KDM4E 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.